HICPAC Recommendation Categorization Update Workgroup: Public Comment Summary and Finalization

Similar documents
Understanding the U.S. Preventive Services Task Force and its Conflicts of Interest Policies

Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

Basis for Conclusions: ISA 230 (Redrafted), Audit Documentation

Request for Proposals

Guideline Development at the American College of Physicians. American College of Physicians

Applying Evidence Analysis to the Creation of Evidence Based Guideline and Toolkits

Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

Special guidelines for preparation and quality approval of reviews in the form of reference documents in the field of occupational diseases

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI. Ethical Principles for Biomedical Research Involving Human Beings

Washington, DC, November 9, 2009 Institute of Medicine

May 16, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

Council for Outbreak Response: Healthcare-Associated Infections & Antibiotic-Resistant Pathogens (CORHA) HICPAC December 1, 2016

CMS Issues New Draft Guidance on Coverage with Evidence Development Policy for National Coverage Determinations

CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG)

ACR Appropriateness Criteria Rating Round Information

UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

Clinical Review Report (Sample)

NIDA Rationale Clean 1 09/17/06

World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects

U.S. Preventive Services Task Force Methods and Processes. Alex R. Kemper, MD, MPH, MS June 16, 2014

Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Justice in Research Ethics: International Issues. Nancy E. Kass, ScD Johns Hopkins University

Justice Research and Statistics Association CODE OF ETHICS

Statute: Liability for Failure to Vaccinate

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Complete Summary GUIDELINE TITLE. Cervical cytology screening. BIBLIOGRAPHIC SOURCE(S)

Dear Dr. Kloiber, Our comments on paragraphs 15, 22, and 34 of the April 2013 draft proposal follow. Sincerely,

IRB Policy 5 Research Activities

International Framework for Assurance Engagements

This memo includes background of the project, the major themes within the comments, and specific issues that require further CSAC/HITAC action.

Revision of the CIOMS ethical guidelines for Biomedical Research

TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines

Guideline Development At WHO

Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry

ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations

Complete Summary GUIDELINE TITLE

GATE CAT Intervention RCT/Cohort Studies

Guidance on Returning Research Results to Subjects

FINAL. In accordance with this four-factor analysis, the City of Rochester has balanced the following:

Corporate Medical Policy Investigational (Experimental) Services

Clinical Guidelines And Primary Care

Nova Scotia Board of Examiners in Psychology. Custody and Access Evaluation Guidelines

OPTN/UNOS Ethics Committee Report to the Board of Directors June 1-2, 2015 Atlanta, GA. Peter Reese, MD, Chair Elisa Gordon, PhD, MPH, Vice Chair

Part 2: Evidence Evaluation and Management of Conflicts of Interest 2

Recommendations in Opioid Prescribing Guidelines for Chronic Pain

Ethics: Triage First Come, First Serve

MINI SYMPOSIUM - EUMASS - UEMASS European Union of Medicine in Assurance and Social Security

Public Health Masters (MPH) Competencies and Coursework by Major

FDA s Evidence-Based Review System

The ASRM Committee Opinion on PGT for Aneuploidy Our Conclusions and How We Drew Them. Alan Penzias, MD

5.I.1. GENERAL PRACTITIONER ANNOUNCEMENT OF CREDENTIALS IN NON-SPECIALTY INTEREST AREAS

David O. Meltzer* Opportunities in the Economics of Personalized Health Care and Prevention

Cannabis use carries significant health risks, especially for people who use it frequently and or/begin to use it at an early age.

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion

TOBACCO PRODUCT OR MEDICAL PRODUCT?

Evidence Supporting the Recommendations. Implementation of the Guideline. Benefits/Harms of Implementing the Guideline Recommendations

Discussion. Re C (An Adult) 1994

Mental Capacity Implementation Programme. Mental Capacity Act 2005

Quality of Clinical Practice Guidelines

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015

General Chapter/Section: <232> Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No.

Assurance Engagements Other than Audits or Review of Historical Financial Statements

CIHRT Exhibit P-2592 Page 1 APPENDIX. ADAPTE Process for the Treatment of In situ Breast Carcinoma. Eastern Health Breast Disease Site Group

EHR Developer Code of Conduct Frequently Asked Questions

NCCN Clinical Practice Guidelines Development Process

Supplement. NHLBI and ACC/AHA Criteria for Rating Strength of Evidence

Clinical Practice Guideline on Central Venous Catheter Care for the Patient with Cancer

OUTCOMES SUMMARY REPORT

IMPORTANT DISCLAIMER. Note

Guide to Rating Critical & Integrative Thinking for eportfolios Washington State University, Fall 2006

GRADE, Summary of Findings and ConQual Workshop

2) Ethical and scientific standards that guide the use of quarantine or other movement restrictions during public health emergencies.

INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION CONTENTS

Guideline for Fertility Preservation for Patients with Cancer

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) proposes to amend its medical

January 2, Overview

MedXellence Medical Incident Analysis: Group Exercise. Guidance Materials for the Patient Safety Video Presentation

NIOSH Respiratory Protective Device Priorities - Opportunities for International Collaboration

Number: III-45 Effective Date: 1 February 2012 Revised Date: November 2016

APPENDIX A. THE UNIVERSITY OF OKLAHOMA Student Rights and Responsibilities Code PROCEDURES

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014

Guidelines for Ethical Conduct of Behavioral Projects Involving Human Participants by High School Students

See Important Reminder at the end of this policy for important regulatory and legal information.

FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions

Should Cochrane apply error-adjustment methods when conducting repeated meta-analyses?

Research on Medical Practices: Why Patients Consider Participating and the Investigational Misconception

Amherst College Title IX Office

ALCOHOL POLICY ALCOHOLIC BEVERAGE POLICY

Dental Legal Case Study

Software as a Medical Device (SaMD)

US Preventive Services Task Force : Who we are, What we do, and How we hope to work with you

The Evidence Is So Clear. The Evidence Is So Clear

Pre-Employment Psychological Evaluation Guidelines

Centers for Disease Control and Prevention. CDC Sex-Specific Body Mass Index (BMI)-For-Age Growth Charts

Strategies for Federal Agencies

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary

Draft Accreditation Report for consultation

I. HSC Review and Approval of Research Involving Children

Transcription:

HICPAC Categorization Update Workgroup: Public Comment Summary and Finalization Deborah Yokoe and Daniel Diekema, Workgroup Co-Chairs HICPAC Presentation, November 2018

Disclaimer: The findings and conclusions herein are draft and have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy.

Background How can HICPAC: Simplify its recommendation categories? Improve transparency around the rationale for choosing specific recommendation categories? Address practices for which evidence is scant or absent? Address bundled practices? HICPAC Categorization Workgroup activities: Monthly Workgroup calls Discussion at HICPAC meetings: 07/2017, 11/2017, 02/2018 Test draft scheme with CAUTI Guideline NICU Guideline Workgroup experience

Table 1: Overall Strength of s Strength Definition Implied Obligation Language A means that we are confident that the benefits of the recommended approach clearly exceed the harms (or, in the case of a negative recommendation, that the harms clearly exceed the benefits). In general, s should be supported by high- to moderate-quality evidence. In some circumstances, however, s may be made based on lesser evidence or even expert opinion when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms or when the is required by federal law. A implies that healthcare personnel/healthcare facilities should implement the recommended approach unless a clear and compelling rationale for an alternative approach is present. The wording of the should specify the setting and population to which the applies (e.g., adult patients in intensive care unit settings) Declarative verbs, e.g., use, perform, maintain, replace Should, should not Recommend/ is recommended, recommend against/ is not recommended Is indicated/ is not indicated Conditional No A Conditional means that we have determined that the benefits of the recommended approach are likely to exceed the harms (or, in the case of a negative recommendation, that the harms are likely to exceed the benefits). Conditional s may be supported by either low-, moderate- or high-quality evidence when: there is high-quality evidence, but the benefit/harm balance is not clearly tipped in one direction the evidence is weak enough to cast doubt on whether the recommendation will consistently lead to benefit the likelihood of benefit for a specific patient population or clinical situation is extrapolated from relatively high-quality evidence demonstrating impact on other patient populations or in other clinical situations (e.g., evidence obtained during outbreaks used to support probable benefit during endemic periods) the impact of the specific intervention is difficult to disentangle from the impact of other simultaneously implemented interventions (e.g., studies evaluating bundled practices) there appears to be benefit based on available evidence, but the benefit/harm balance may change with further research benefit is most likely if the intervention is used as a supplemental measure in addition to basic practices No is made when there is both a lack of pertinent evidence and an unclear balance between benefits and harms. A Conditional implies that healthcare facilities/ personnel could, or could consider implementing the recommended approach. The degree of appropriateness may vary depending on the benefit vs. harm balance for the specific setting. The wording of the Conditional should specify the setting and population to which the Conditional applies when relevant, including: select settings (e.g., during outbreaks) select environments (e.g., ICUs) select populations (e.g., neonates, transplant patients) Consider Could May/ may consider No recommendation can be made regarding

Table 1: Strength Definition Implied Obligation Language A means that we are confident that the benefits of the recommended approach clearly exceed the harms (or, in the case of a negative recommendation, that the harms clearly exceed the benefits). In general, s should be supported by high- to moderatequality evidence. In some circumstances, however, s may be made based on lesser evidence or even expert opinion when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms or when the is required by federal law. A implies that healthcare personnel/healthcare facilities should implement the recommended approach unless a clear and compelling rationale for an alternative approach is present. The wording of the should specify the setting and population to which the applies (e.g., adult patients in intensive care unit settings) Declarative verbs, e.g., use, perform, maintain, replace Should, should not Recommend/ is recommended, recommend against/ is not recommended Is indicated/ is not indicated

Table 1: Conditional Strength Definition Implied Obligation Language Conditional A Conditional means that we have determined that the benefits of the recommended approach are likely to exceed the harms (or, in the case of a negative recommendation, that the harms are likely to exceed the benefits). Conditional s may be supported by either low-, moderate- or high-quality evidence when: there is high-quality evidence, but the benefit/harm balance is not clearly tipped in one direction the evidence is weak enough to cast doubt on whether the recommendation will consistently lead to benefit the likelihood of benefit for a specific patient population or clinical situation is extrapolated from relatively high-quality evidence demonstrating impact on other patient populations or in other clinical situations (e.g., evidence obtained during outbreaks used to support probable benefit during endemic periods) the impact of the specific intervention is difficult to disentangle from the impact of other simultaneously implemented interventions (e.g., studies evaluating bundled practices) there appears to be benefit based on available evidence, but the benefit/harm balance may change with further research benefit is most likely if the intervention is used as a supplemental measure in addition to basic practices A Conditional implies that healthcare facilities/ personnel could, or could consider implementing the recommended approach. The degree of appropriateness may vary depending on the benefit vs. harm balance for the specific setting. The wording of the Conditional should specify the setting and population to which the Conditional applies when relevant, including: select settings (e.g., during outbreaks) select environments (e.g., ICUs) select populations (e.g., neonates, transplant patients) Consider Could May/ may consider

Table 1: No Strength Definition Implied Obligation Language No No is made when there is both a lack of pertinent evidence and an unclear balance between benefits and harms. No recommendation can be made regarding

Table 2: Justification for Choice of Components What to include Comments Aggregate evidence quality See below (Table 3) Benefit List the favorable changes in outcomes that would likely occur if the recommendation were followed. Be explicit, clear about pros/cons Risks and harms Benefit-harm assessment List the adverse events or other unfavorable outcomes that may occur if the recommendation were followed. Classify as preponderance of benefit over harm (or vice versa) or a balance of benefit and harm. Description of this balance can be from the individual patient perspective, the societal perspective, or both. Be explicit, clear about pros/cons s are possible when clear benefit is not offset by important harms or costs (or vice versa); conversely, when the benefit is small or offset by important adverse factors, the balance between benefit and harm prevents a. Resource use Value judgments Describe (if applicable) direct costs, opportunity costs, material or human resources requirements, facility needs, etc., that may be associated with following the recommendation. Summarize value judgments used by the group in creating the recommendation; if none were involved, state none HICPAC does not perform its own cost analyses and is not obliged to address cost if analyses are not available and no useful statements can be made. State clearly if information on resource use is lacking. Translating evidence into action often involves value judgments, which include guiding principles, ethical considerations, or other beliefs and priorities; stating them clearly helps users understand their influence on interpreting objective evidence. Intentional vagueness State reasons for any intentional vagueness in the recommendation; if none was intended, state none s should be clear and specific, but if the group chooses to be vague, acknowledging their reasoning clearly promotes transparency. Reasons for vagueness may include insufficient evidence; inability to achieve consensus among panel regarding evidence quality, anticipated benefits/harms, or interpretation of evidence; legal considerations; economic reasons; ethical/religious issues. Exceptions List situations or circumstances where the recommendation should not be applied

Table 2, Part 1 Components What to include Comments Supporting evidence See below Number and type of available evidence Confidence in Evidence Benefit Level of confidence is low/moderate/high (Table 3) List the favorable changes in outcomes that would likely occur if the recommendation were followed. used, eg, 10 observational studies eg, The level of confidence in this evidence is low as observational studies are at increased risk of bias Be explicit, clear about pros/cons Risks and harms Benefit-harm assessment List the adverse events or other unfavorable outcomes that may occur if the recommendation were followed. Classify as preponderance of benefit over harm (or vice versa) or a balance of benefit and harm. Description of this balance can be from the individual patient perspective, the societal perspective, or both. Be explicit, clear about pros/cons s are possible when clear benefit is not offset by important harms or costs (or vice versa); conversely, when the benefit is small or offset by important adverse factors, the balance between benefit and harm prevents a. Resource use Describe (if applicable) direct costs, opportunity costs, material or human resources requirements, facility needs, etc., that may be associated with following the recommendation. HICPAC does not perform its own cost analyses and is not obliged to address cost if analyses are not available and no useful statements can be made. State clearly if information on resource use is lacking.

Table 2, Part 2 Components What to include Comments Value judgments Summarize value judgments used by the group in creating the recommendation; if none were involved, state none Translating evidence into action often involves value judgments, which include guiding principles, ethical considerations, or other beliefs and priorities; stating them clearly helps users understand their influence on interpreting objective Intentional vagueness State reasons for any intentional vagueness in the recommendation; if none was intended, state none evidence. s should be clear and specific, but if the group chooses to be vague, acknowledging their reasoning clearly promotes transparency. Reasons for vagueness may include insufficient evidence; inability to achieve consensus among panel regarding evidence quality, anticipated benefits/harms, or interpretation of evidence; legal considerations; economic reasons; ethical/religious issues. Exceptions List situations or circumstances where the recommendation should not be applied

Table 3: Level of Confidence in the Evidence Level of Confidence in the Evidence for Each Highly confident that the true effect lies close to that of the estimated size and direction of the effect. For example, confidence High is rated as High when there are multiple studies with no major limitations, there are consistent findings, and the summary estimate has a narrow confidence interval. The true effect is likely to be close to the estimated size and direction of the effect, but there is a possibility that it is substantially different. For example, confidence is rated as Moderate Moderate when there are only a few studies and some have limitations but not major flaws, there is some variation between study results, or the confidence interval of the summary estimate is wide. The true effect may be substantially different from the estimated size and direction of the effect. For example, confidence is rated as Low when supporting studies have major flaws, there is Low important variation between study results, the confidence interval of the summary estimate is very wide, or there are no rigorous studies. Based on Grades of, Assessment, Development, and Evaluation (GRADE) and the Canadian Task Force on Preventive Health Care

Public Comment Period Announced in the Federal Register on September 17, 2018 (Docket # CDC-2018-0090) Was available for public review and comment on www.regulations.gov until October 17, 2018 No comments from the public were received

Questions Discussion